Primary brain tumours and specific serum immunoglobulin E: A case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort

B. Schlehofer, B. Siegmund, J. Linseisen, J. Schüz, S. Rohrmann, S. Becker, D. Michaud, B. Melin, H. Bas Bueno-De-Mesquita, P. H M Peeters, P. Vineis, A. Tjonneland, A. Olsen, K. Overvad, I. Romieu, H. Boeing, K. Aleksandrova, A. Trichopoulou, C. Bamia, P. LagiouC. Sacerdote, D. Palli, S. Panico, S. Sieri, R. Tumino, M. J. Sanchez, L. Rodriguez, M. Dorronsoro, E. J. Duell, M. D. Chirlaque, A. Barricarte, S. Borgquist, J. Manjer, V. Gallo, N. E. Allen, T. J. Key, E. Riboli, R. Kaaks, J. Wahrendorf

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Case-control studies suggest that patients with allergic diseases have a lower risk of developing glioma but not meningioma or schwannoma. However, those data can be differentially biased. Prospective studies with objective measurements of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained before cancer diagnosis could help to clarify whether an aetiological association exists. Methods: The present case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) measured specific serum IgE as a biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma and 49 schwannoma cases and 963 matched controls using the ImmunoCAP specific IgE test. Subjects with an IgE level ≥0.35 kUA/l (kilo antibody units per litre) were classified as sensitized by allergens. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by adjusted conditional logistic regression models for each tumour subtype. The effect of dose-response relationship was assessed in five increasing IgE level categories to estimate P-values for trend. Results: The risk of glioma was inversely related to allergic sensitization (OR = 0.73; 95% CI 0.51-1.06), especially pronounced in women (OR = 0.53; 95% CI 0.30-0.95). In dose-response analyses, for high-grade glioma, the lowest OR was observed in sera with the highest IgE levels (P for trend = 0.04). No association was seen for meningioma and schwannoma. Conclusion: The results, based on serum samples prospectively collected in a cohort study, provide some support for the hypothesis that individuals with allergic sensitization are at reduced risk of glioma and confirm results from previous case-control studies.

Original languageEnglish
Pages (from-to)1434-1441
Number of pages8
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume66
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Brain Neoplasms
Immunoglobulin E
Case-Control Studies
Glioma
Neurilemmoma
Meningioma
Serum
Odds Ratio
Neoplasms
Confidence Intervals
Allergens
Biomarkers
Logistic Models
Cohort Studies
Prospective Studies
Antibodies

Keywords

  • allergens
  • brain tumours
  • epidemiology
  • immunoglobulin E
  • immunologic tests

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Primary brain tumours and specific serum immunoglobulin E : A case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. / Schlehofer, B.; Siegmund, B.; Linseisen, J.; Schüz, J.; Rohrmann, S.; Becker, S.; Michaud, D.; Melin, B.; Bas Bueno-De-Mesquita, H.; Peeters, P. H M; Vineis, P.; Tjonneland, A.; Olsen, A.; Overvad, K.; Romieu, I.; Boeing, H.; Aleksandrova, K.; Trichopoulou, A.; Bamia, C.; Lagiou, P.; Sacerdote, C.; Palli, D.; Panico, S.; Sieri, S.; Tumino, R.; Sanchez, M. J.; Rodriguez, L.; Dorronsoro, M.; Duell, E. J.; Chirlaque, M. D.; Barricarte, A.; Borgquist, S.; Manjer, J.; Gallo, V.; Allen, N. E.; Key, T. J.; Riboli, E.; Kaaks, R.; Wahrendorf, J.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 66, No. 11, 11.2011, p. 1434-1441.

Research output: Contribution to journalArticle

Schlehofer, B, Siegmund, B, Linseisen, J, Schüz, J, Rohrmann, S, Becker, S, Michaud, D, Melin, B, Bas Bueno-De-Mesquita, H, Peeters, PHM, Vineis, P, Tjonneland, A, Olsen, A, Overvad, K, Romieu, I, Boeing, H, Aleksandrova, K, Trichopoulou, A, Bamia, C, Lagiou, P, Sacerdote, C, Palli, D, Panico, S, Sieri, S, Tumino, R, Sanchez, MJ, Rodriguez, L, Dorronsoro, M, Duell, EJ, Chirlaque, MD, Barricarte, A, Borgquist, S, Manjer, J, Gallo, V, Allen, NE, Key, TJ, Riboli, E, Kaaks, R & Wahrendorf, J 2011, 'Primary brain tumours and specific serum immunoglobulin E: A case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort', Allergy: European Journal of Allergy and Clinical Immunology, vol. 66, no. 11, pp. 1434-1441. https://doi.org/10.1111/j.1398-9995.2011.02670.x
Schlehofer, B. ; Siegmund, B. ; Linseisen, J. ; Schüz, J. ; Rohrmann, S. ; Becker, S. ; Michaud, D. ; Melin, B. ; Bas Bueno-De-Mesquita, H. ; Peeters, P. H M ; Vineis, P. ; Tjonneland, A. ; Olsen, A. ; Overvad, K. ; Romieu, I. ; Boeing, H. ; Aleksandrova, K. ; Trichopoulou, A. ; Bamia, C. ; Lagiou, P. ; Sacerdote, C. ; Palli, D. ; Panico, S. ; Sieri, S. ; Tumino, R. ; Sanchez, M. J. ; Rodriguez, L. ; Dorronsoro, M. ; Duell, E. J. ; Chirlaque, M. D. ; Barricarte, A. ; Borgquist, S. ; Manjer, J. ; Gallo, V. ; Allen, N. E. ; Key, T. J. ; Riboli, E. ; Kaaks, R. ; Wahrendorf, J. / Primary brain tumours and specific serum immunoglobulin E : A case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. In: Allergy: European Journal of Allergy and Clinical Immunology. 2011 ; Vol. 66, No. 11. pp. 1434-1441.
@article{d247bf09eee84489b60668d1ebe1fedb,
title = "Primary brain tumours and specific serum immunoglobulin E: A case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort",
abstract = "Background: Case-control studies suggest that patients with allergic diseases have a lower risk of developing glioma but not meningioma or schwannoma. However, those data can be differentially biased. Prospective studies with objective measurements of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained before cancer diagnosis could help to clarify whether an aetiological association exists. Methods: The present case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) measured specific serum IgE as a biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma and 49 schwannoma cases and 963 matched controls using the ImmunoCAP specific IgE test. Subjects with an IgE level ≥0.35 kUA/l (kilo antibody units per litre) were classified as sensitized by allergens. Odds ratios (OR) and 95{\%} confidence intervals (CI) were estimated by adjusted conditional logistic regression models for each tumour subtype. The effect of dose-response relationship was assessed in five increasing IgE level categories to estimate P-values for trend. Results: The risk of glioma was inversely related to allergic sensitization (OR = 0.73; 95{\%} CI 0.51-1.06), especially pronounced in women (OR = 0.53; 95{\%} CI 0.30-0.95). In dose-response analyses, for high-grade glioma, the lowest OR was observed in sera with the highest IgE levels (P for trend = 0.04). No association was seen for meningioma and schwannoma. Conclusion: The results, based on serum samples prospectively collected in a cohort study, provide some support for the hypothesis that individuals with allergic sensitization are at reduced risk of glioma and confirm results from previous case-control studies.",
keywords = "allergens, brain tumours, epidemiology, immunoglobulin E, immunologic tests",
author = "B. Schlehofer and B. Siegmund and J. Linseisen and J. Sch{\"u}z and S. Rohrmann and S. Becker and D. Michaud and B. Melin and {Bas Bueno-De-Mesquita}, H. and Peeters, {P. H M} and P. Vineis and A. Tjonneland and A. Olsen and K. Overvad and I. Romieu and H. Boeing and K. Aleksandrova and A. Trichopoulou and C. Bamia and P. Lagiou and C. Sacerdote and D. Palli and S. Panico and S. Sieri and R. Tumino and Sanchez, {M. J.} and L. Rodriguez and M. Dorronsoro and Duell, {E. J.} and Chirlaque, {M. D.} and A. Barricarte and S. Borgquist and J. Manjer and V. Gallo and Allen, {N. E.} and Key, {T. J.} and E. Riboli and R. Kaaks and J. Wahrendorf",
year = "2011",
month = "11",
doi = "10.1111/j.1398-9995.2011.02670.x",
language = "English",
volume = "66",
pages = "1434--1441",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Primary brain tumours and specific serum immunoglobulin E

T2 - A case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort

AU - Schlehofer, B.

AU - Siegmund, B.

AU - Linseisen, J.

AU - Schüz, J.

AU - Rohrmann, S.

AU - Becker, S.

AU - Michaud, D.

AU - Melin, B.

AU - Bas Bueno-De-Mesquita, H.

AU - Peeters, P. H M

AU - Vineis, P.

AU - Tjonneland, A.

AU - Olsen, A.

AU - Overvad, K.

AU - Romieu, I.

AU - Boeing, H.

AU - Aleksandrova, K.

AU - Trichopoulou, A.

AU - Bamia, C.

AU - Lagiou, P.

AU - Sacerdote, C.

AU - Palli, D.

AU - Panico, S.

AU - Sieri, S.

AU - Tumino, R.

AU - Sanchez, M. J.

AU - Rodriguez, L.

AU - Dorronsoro, M.

AU - Duell, E. J.

AU - Chirlaque, M. D.

AU - Barricarte, A.

AU - Borgquist, S.

AU - Manjer, J.

AU - Gallo, V.

AU - Allen, N. E.

AU - Key, T. J.

AU - Riboli, E.

AU - Kaaks, R.

AU - Wahrendorf, J.

PY - 2011/11

Y1 - 2011/11

N2 - Background: Case-control studies suggest that patients with allergic diseases have a lower risk of developing glioma but not meningioma or schwannoma. However, those data can be differentially biased. Prospective studies with objective measurements of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained before cancer diagnosis could help to clarify whether an aetiological association exists. Methods: The present case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) measured specific serum IgE as a biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma and 49 schwannoma cases and 963 matched controls using the ImmunoCAP specific IgE test. Subjects with an IgE level ≥0.35 kUA/l (kilo antibody units per litre) were classified as sensitized by allergens. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by adjusted conditional logistic regression models for each tumour subtype. The effect of dose-response relationship was assessed in five increasing IgE level categories to estimate P-values for trend. Results: The risk of glioma was inversely related to allergic sensitization (OR = 0.73; 95% CI 0.51-1.06), especially pronounced in women (OR = 0.53; 95% CI 0.30-0.95). In dose-response analyses, for high-grade glioma, the lowest OR was observed in sera with the highest IgE levels (P for trend = 0.04). No association was seen for meningioma and schwannoma. Conclusion: The results, based on serum samples prospectively collected in a cohort study, provide some support for the hypothesis that individuals with allergic sensitization are at reduced risk of glioma and confirm results from previous case-control studies.

AB - Background: Case-control studies suggest that patients with allergic diseases have a lower risk of developing glioma but not meningioma or schwannoma. However, those data can be differentially biased. Prospective studies with objective measurements of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained before cancer diagnosis could help to clarify whether an aetiological association exists. Methods: The present case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) measured specific serum IgE as a biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma and 49 schwannoma cases and 963 matched controls using the ImmunoCAP specific IgE test. Subjects with an IgE level ≥0.35 kUA/l (kilo antibody units per litre) were classified as sensitized by allergens. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by adjusted conditional logistic regression models for each tumour subtype. The effect of dose-response relationship was assessed in five increasing IgE level categories to estimate P-values for trend. Results: The risk of glioma was inversely related to allergic sensitization (OR = 0.73; 95% CI 0.51-1.06), especially pronounced in women (OR = 0.53; 95% CI 0.30-0.95). In dose-response analyses, for high-grade glioma, the lowest OR was observed in sera with the highest IgE levels (P for trend = 0.04). No association was seen for meningioma and schwannoma. Conclusion: The results, based on serum samples prospectively collected in a cohort study, provide some support for the hypothesis that individuals with allergic sensitization are at reduced risk of glioma and confirm results from previous case-control studies.

KW - allergens

KW - brain tumours

KW - epidemiology

KW - immunoglobulin E

KW - immunologic tests

UR - http://www.scopus.com/inward/record.url?scp=80053963573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053963573&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.2011.02670.x

DO - 10.1111/j.1398-9995.2011.02670.x

M3 - Article

C2 - 21726235

AN - SCOPUS:80053963573

VL - 66

SP - 1434

EP - 1441

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 11

ER -